N/A N=10 Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study
Small Fiber Neuropathy
Primary: AFI-intensity After Nociceptive Stimulation — 0.60; 0.25; 0.50 unitless
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=11 Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy
Idiopathic Small Fiber Neuropathy
Primary: Visual Analogue Score for Pain Intensity. — 7.1; 6.9; 7.3; 5.4 score on visual analogue score
Phase 2 N=20 IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3
Small Fiber Neuropathy · Idiopathic Peripheral Neuropathy
Primary: The Change in Nerve Fiber Density Between Visits 1 and 8. — 0.5; 0.6 fibers/mm
N/A N=102 Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
Small Fiber Neuropathy · Fabry Disease · Ehlers Danlos Syndrome
Primary: Number of Patients With Abnormal Electrochemical Skin Conductance in the Different Study Groups Who Have Clinical Symptoms Consistent With Small Fiber Polyneuropathy…
Phase 4 N=20 Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Trigeminal Neuralgia · Glossopharyngeal Neuralgia
Primary: Change in Pain Score — -0.6224; -1.005; -0.8102; -1.079 score on a scale
Phase 2 N=89 A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy
Small Fiber Neuropathy
Primary: Change in Weekly Average of Daily Pain Intensity on the 11 Point NRS — -2.018; -0.933 units on a scale — p=<0.0001
Phase 2 N=45 Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration
Small Fiber Neuropathy
Primary: Denervation of Skin — 0.1; 0.1 percent change — p=0.33
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
N/A N=34 Lidocaine for Diabetic Peripheral Neuropathy
Diabetes · Peripheral Neuropathy · Pain
Primary: Change in Spontaneous Pain at 60-120 Minutes After Lidocaine Infusion Initiated (Assessed on 0-10 NRS) — 33; 51 percentage of pain change from baseline — p=0.03
N/A N=22 Nociceptive Pain Fiber Response
Painful Peripheral Diabetic Neuropathy
Primary: Changes in Small Nerve Fiber Density by Assessment of a Skin Biopsy Comparing Baseline to Day 60 — .1; .1 nerve fibers / mm squared
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
Phase 4 N=402 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…
N/A N=42 A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced Peripheral Neuropathy
Primary: Aδ:C Fiber Detection Threshold Ratio — 2.04; 1.57 ratio — p=0.05
N/A N=161 Symptom Management Efficacy Study to Reduce Distal Neuropathic Pain
Neuropathic Pain · HIV Neuropathy · HIV/AIDS
Primary: Gracely Pain Scale (GPS) — -2.51; -1.96; -2.38; -0.99 GPS pain score on a scale
N/A N=10 Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation
Painful Diabetic Neuropathy
Primary: Pain Assessment — 6.5; 1.0 score on a scale
Phase 2 N=18 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
N/A N=26 Pregabalin in CIPN
Neuropathy · Pain
Primary: Change in Spontaneous Pain Intensity as a Function of Baseline MPT — -0.0179; -0.0172 Pearson correlation coefficient
N/A N=1,270 Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy
Primary: Change in Patient Quality of Life at Baseline and 8 Months — 0.66; 0.65; 0.68; 0.68 units on a scale
Phase 2 N=14 MC-5A for Chemotherapy Induced Peripheral Neuropathy
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
N/A N=44 Corneal Nerves Function and Structure
Diabetic Peripheral Neuropathy
Primary: Cornea Sensitivity — 0.177; 0.293 time ratio of eyelids closed vs. open — p=<0.001
Phase 2 N=40 Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
N/A N=148 Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study
HIV · Sensory Neuropathy · Neuropathic Pain
Primary: Neuropathic Element of Pain Using the Doleur Neuropathique 4 Interview — 81; 67 Participants
Phase 4 N=40 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy
Diabetic Neuropathy
Primary: Assessing the Change in Resting Blood Pressure Upon Treatment of Pregabalin vs. Placebo in Patients With Diabetes and Peripheral Neuropathy. — -7.63; -8.98; -4.41; -4.93…
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
N/A N=63 Chronic Neuropathy Following Chemotherapy
Peripheral Nervous System Diseases · Chronic Pain
Primary: Chemotherapy-induced Peripheral Neuropathy — 21 participants
Phase 3 N=61 Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy
Type 1 Diabetes · Peripheral Neuropathy
Primary: Skin Biopsy - Intraepidermal Nerve Fiber Density (IENFD) - Distal Thigh — 12; 14 Percentage change in IENFD
Phase 3 N=256 Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Neuropathic Pain
Primary: Neuropathic Pain in Subjects With Peripheral Neuropathic Pain Conditions During the Double-blind Phase — 2.84; 3.62 score on scale — p=0.0018
N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05
N/A N=22 Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis
Adiposity
Primary: Vibration Detection Threshold (VDT) — 26.3; 19 (um/sec)